New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development
- PMID: 19075046
- PMCID: PMC2650526
- DOI: 10.1128/AAC.00749-08
New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development
References
-
- Acocella, G. 1978. Clinical pharmacokinetics of rifampicin. Clin. Pharmacokinet. 3:108-127. - PubMed
-
- Alangaden, G. J., and S. A. Lerner. 1997. The clinical use of fluoroquinolones for the treatment of mycobacterial diseases. Clin. Infect. Dis. 25:1213-1221. - PubMed
-
- Andries, K., P. Verhasselt, J. Guillemont, H. W. Gohlmann, J. M. Neefs, H. Winkler, G. J. Van, P. Timmerman, M. Zhu, E. Lee, P. Williams, D. de Chaffoy, E. Huitric, S. Hoffner, E. Cambau, C. Truffot-Pernot, N. Lounis, and V. Jarlier. 2005. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307:223-227. - PubMed
-
- Arrora, S. K., N. Sinha, R. Sinha, R. Bateja, S. Sharma, and R. S. Upadhayaya. 2004. Design, synthesis, modelling and activity of novel anti tubercular compounds, abstr. 63. Abstr. Am. Chem. Soc. Meet.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
